J&J warns doctors not to count on Prezista as a COVID-19 treatment

Drugmakers are looking at all options for a possible therapeutic for COVID-19 as the novel coronavirus pandemic continues its spread. One area with some promise? HIV meds––but one drugmaker is tamping down hopes in that arena based on a lack of supporting data.

As at least one other Big Pharma works to repurpose an HIV-fighter to treat COVID-19, Johnson & Johnson shot down chances of doing the same with Prezista (darunavir), at least for now.